用聚乙二醇干扰素α-2b治疗的一位年轻真性红细胞增多症患者染色体异常消失。 - Suppr

Suppr

超能文献

Disappearance of a chromosomal abnormality in a young patient with polycythemia vera treated with ropeginterferon alfa-2b.

作者信息

Hosoda Rina, Hashimoto Yoshinori, Hara Kentaro, Maegaki Masaya, Suzuki Sayaka, Hosoda Yuzuru, Kawamura Koji

机构信息

Department of Hematology, Tottori University Hospital, Tottori, Japan.

Department of Hematology, Tottori Prefectural Central Hospital, 730 Ezu, Tottori CityTottori, 680-0901, Japan.

出版信息

Ann Hematol. 2024 Sep;103(9):3825-3827. doi: 10.1007/s00277-024-05909-3. Epub 2024 Jul 25.

DOI:10.1007/s00277-024-05909-3

PMID:39052033

Abstract

摘要

相似文献

Disappearance of a chromosomal abnormality in a young patient with polycythemia vera treated with ropeginterferon alfa-2b.用聚乙二醇干扰素α-2b治疗的一位年轻真性红细胞增多症患者染色体异常消失。

Ann Hematol. 2024 Sep;103(9):3825-3827. doi: 10.1007/s00277-024-05909-3. Epub 2024 Jul 25.

Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.聚乙二醇干扰素α-2b用于真性红细胞增多症患者的治疗。

Drugs Today (Barc). 2020 Mar;56(3):195-202. doi: 10.1358/dot.2020.56.3.3107706.

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.聚乙二醇干扰素α-2b对比真性红细胞增多症标准疗法（PROUD-PV和CONTINUATION-PV）：一项随机、非劣效性3期试验及其扩展研究。

Lancet Haematol. 2020 Mar;7(3):e196-e208. doi: 10.1016/S2352-3026(19)30236-4. Epub 2020 Jan 31.

Mechanism of Action of Ropeginterferon Alfa-2b in Polycythemia Vera Treatment.聚乙二醇干扰素α-2b治疗真性红细胞增多症的作用机制

Clin Ther. 2024 May;46(5):439-440. doi: 10.1016/j.clinthera.2024.03.005. Epub 2024 May 1.

Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.罗哌戈汀干扰素 α-2b 与放血疗法治疗低危真性红细胞增多症患者（Low-PV 研究）：一项多中心、随机 2 期临床试验。

Lancet Haematol. 2021 Mar;8(3):e175-e184. doi: 10.1016/S2352-3026(20)30373-2. Epub 2021 Jan 18.

A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.罗特西普干扰素 α-2b 治疗真性红细胞增多症的药代动力学评价。

Expert Opin Drug Metab Toxicol. 2021 Jan;17(1):3-7. doi: 10.1080/17425255.2021.1839050. Epub 2020 Oct 29.

Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b.在接受罗特西普干扰素 alfa-2b 治疗的低危原发性血小板增多症日本患者中的疗效和安全性结局。

Int J Hematol. 2024 Aug;120(2):151-156. doi: 10.1007/s12185-024-03804-1. Epub 2024 Jul 1.

Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo.罗特西普α-2b 在体外和体内靶向 JAK2V617F 阳性真性红细胞增多症细胞。

Blood Cancer J. 2018 Oct 4;8(10):94. doi: 10.1038/s41408-018-0133-0.

Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera.聚乙二醇干扰素α-2b治疗真性红细胞增多症患者的暴露-疗效和暴露-安全性分析。

Br J Clin Pharmacol. 2024 Jun;90(6):1493-1502. doi: 10.1111/bcp.16043. Epub 2024 Mar 19.

Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.聚乙二醇干扰素α-2b，一种新型的干扰素α-2b，在真性红细胞增多症患者中诱导出高缓解率且毒性低。

Blood. 2015 Oct 8;126(15):1762-9. doi: 10.1182/blood-2015-04-637280. Epub 2015 Aug 10.

本文引用的文献

FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN).标题：Fedratinib 联合 Nivolumab 治疗对 JAK 抑制剂治疗有抵抗或疗效不佳的骨髓纤维化患者的 II 期研究方案：德国 MPN 研究小组（GSG-MPN）

Ann Hematol. 2024 Aug;103(8):2775-2785. doi: 10.1007/s00277-024-05867-w. Epub 2024 Jul 5.

Targeting exhausted cytotoxic T cells through CTLA-4 inhibition promotes elimination of neoplastic cells in human myelofibrosis xenografts.通过 CTLA-4 抑制靶向耗尽的细胞毒性 T 细胞可促进人骨髓纤维化异种移植物中肿瘤细胞的消除。

Am J Hematol. 2024 Oct;99(10):1939-1950. doi: 10.1002/ajh.27428. Epub 2024 Jul 2.

Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.聚乙二醇干扰素治疗低危真性红细胞增多症的2期随机研究：5年药物生存情况及疗效结果

Ann Hematol. 2024 Feb;103(2):437-442. doi: 10.1007/s00277-023-05577-9. Epub 2023 Dec 7.

Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment.接受罗培戈干扰素α-2b治疗与最佳可用治疗的真性红细胞增多症患者的无事件生存期

Leukemia. 2023 Oct;37(10):2129-2132. doi: 10.1038/s41375-023-02008-6. Epub 2023 Aug 26.

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.芦可替尼与最佳可用疗法治疗不耐受或对羟基脲耐药的真性红细胞增多症的随机试验。

J Clin Oncol. 2023 Jul 1;41(19):3534-3544. doi: 10.1200/JCO.22.01935. Epub 2023 May 1.

Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs.儿童和青少年骨髓增生性肿瘤的真实世界研究：识别风险和未满足的需求。

Blood Adv. 2022 Sep 13;6(17):5171-5183. doi: 10.1182/bloodadvances.2022007201.

Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera.原发性骨髓纤维化中细胞遗传学异常的特征和临床意义。

Haematologica. 2017 Sep;102(9):1511-1518. doi: 10.3324/haematol.2017.165795. Epub 2017 May 4.

Cardiovascular events and intensity of treatment in polycythemia vera.原发性骨髓纤维化患者的心血管事件和治疗强度。

N Engl J Med. 2013 Jan 3;368(1):22-33. doi: 10.1056/NEJMoa1208500. Epub 2012 Dec 8.

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.原发性血小板增多症和真性红细胞增多症的反应标准：欧洲白血病网共识会议的结果

Blood. 2009 May 14;113(20):4829-33. doi: 10.1182/blood-2008-09-176818. Epub 2009 Mar 10.

Possible selective effects of interferon alpha-2b on a malignant clone in a case of polycythemia vera.

Ann Hematol. 1993 Mar;66(3):161-2. doi: 10.1007/BF01697629.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验